In our study, we integrated genomic biomarkers and tumor microenvironment biomarkers and found that patients with high TMB and a high ratio of CD8 T lymphocytes to M2 macrophages had a higher response rate to chemotherapy in TNBC. The gene discussed is CD8A; the disease is neoplasm.